Dr. David Rozzell earned a Ph.D. In chemistry from Harvard University and has spent 25 years working in the biotechnology industry with a specialization in the area of biocatalysis and chiral synthesis. Most recently, Dr. Rozzell was the founder and CEO of BioCatalytics, Inc, a company specializing in the development of novel enzymes for the pharmaceutical industry. . BioCatalytics, Inc. was acquired by Codexis, Inc. in July 2007.

Professor John F. Hartwig is the Henry Rapoport Professor of Chemistry at the Univertsity of clifornia at Berkeley, moving from his previous position at the University of Illinois in mid-2011. Professor Hartwig's research focuses on the discovery and understanding of new reactions catalyzed by transition metal complexes. In addition to technology on fluoralkylation licensed to Catylix, he has developed numerous other chemistries used world-wide.

Dr. Brian Adger has more than 35 years experience in the pharmaceutical and chemical industries. He has held senior positions at SmithKline French (now GSK), Sterling Drug (now part of Sanofi), Great Lakes Chemical Corporation and was a founding director of Chiroscience Ltd. Since 1997 Dr. Adger has been an independent consultant and has consulted for more than 50 companies internationally. Currently he is Chairman of the SAB for Johnson Matthey.